STUDY OF SELECTIVE BRAF KINASE INHIBITOR DABRAFENIB MONOTHERAPY TWICE DAILY AND IN COMBINATION WITH DABRAFENIB TWICE DAILY AND TRAMETINIB ONCE DAILY IN COMBINATION THERAPY IN SUBJECTS WITH BRAF V600E MUTATION POSITIVE METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER.: